publication date: Mar. 9, 2018

In Brief

Ashley named director of Tisch Brain Tumor Center at Duke

David Ashley was named director of the Preston Robert Tisch Brain Tumor Center at Duke. Ashley follows Darell Bigner, who became director emeritus on Feb. 1.

Bigner will continue to lead the work with the modified poliovirus in an expanding range of glioma and other cancers, including breast carcinoma and melanoma.

Before leaving Australia to join Duke in 2017 as professor of neurosurgery and director of the pediatric neuro-oncology program in the Department of Neurosurgery, Ashley had served as chair of the Department of Medicine at Deakin University, the program director of Cancer Services University Hospital Barwon Health, and executive director of the Western Alliance Academic Health Science Centre.

He was also a director of the Victorian Cancer Agency Consultative Council, director of Clinical Trials Australia, and has been an Academy member of the Australian National Health and Medical Research Council since 2010. Ashley also served as associate professor and director of the Children’s Cancer Center at the Royal Children’s Hospital in Melbourne, the largest children’s cancer treatment center in Australia.

Ashley is credentialed in both pediatric and adult oncology practice. His peer-reviewed publication record is diverse and includes laboratory-based cancer research, clinical trials, public health and psycho-oncology research.

His primary academic focus in brain tumors has been tumor immunology and the genomics and epigenetics of cancer. His achievements in research have led to change in practice in the care of children and adults with brain tumors including the introduction of new standards of practice for the delivery of systemic therapy.

 

Wolin named director at Center for Carcinoid and Neuroendocrine Tumors at Mt. Sinai

Edward Wolin was named director of the Mount Sinai Center for Carcinoid and Neuroendocrine Tumors.

The multidisciplinary center includes Mount Sinai specialists in gastroenterology, surgical oncology, hepatobiliary surgery, thoracic surgery, nuclear medicine, cardiology, medical oncology, radiology, pathology, endocrinology, and nutrition.

Wolin, who will also be a professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai, brings a robust research program that includes clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis.

He becomes the second director of the center which was founded by Richard Warner, professor of medicine (gastroenterology), a pioneer in neuroendocrine tumor research and treatment.

Wolin will lead the center along with Michelle Kang Kim, associate professor of medicine (gastroenterology), and who will serve as associate director after previously serving as interim director.

Wolin was most recently director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care. He has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy.

He was previously director of neuroendocrine tumor programs at the University of Kentucky Medical Center and Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the then-largest carcinoid and neuroendocrine tumor programs in the country.

Wolin serves as co-medical director for the Carcinoid Cancer Foundation and on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research.

 

Cleary named director of IU Walther Supportive Oncology Program

Walther Supportive Oncology Program at Indiana University School of Medicine has named James Cleary as director, where he will join the faculty in July to lead the program and will hold the Walther Senior Chair in Supportive Oncology. He will also be a professor of medicine.

An Australian-trained medical oncologist and palliative care physician, Cleary, who has been in the United States for 24 years, is recognized globally for his expertise in palliative care medicine and cancer pain.

He is currently a professor of medicine at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. He also is a palliative care physician with the UW Health palliative care program, which he started in 1996.

In 2011, he stepped down as medical director of the clinical program to commit more of his efforts to improving global palliative care. He has been director of the Pain and Policy Studies Group, a World Health Organization Collaborating Center for Pain Policy & Palliative Care at the UW Carbone Cancer Center, for the past seven years.

He earned his medical degree from the University of Adelaide in South Australia, and he completed his medical oncology fellowship (Fellow of the Australasian College of Physicians) at the Royal Adelaide Hospital. He was a founding fellow of the Australasian Chapter of Palliative Medicine through his oncology training and laboratory work in opioid pharmacogenetics.

Cleary’s research has been extensively supported by grants from the National Institutes of Health/National Cancer Institute, Livestrong, the Open Society Institute and others.

IU School of Medicine recently received a $14 million gift from the Walther Cancer Foundation to create a supportive oncology program that goes beyond standard therapies such as surgery, chemotherapy, and radiation and seeks to care for a patient’s overall physical, mental, and spiritual well-being. The program is named the Walther Supportive Oncology Program in recognition of the foundation’s generosity.

Copyright (c) 2018 The Cancer Letter Inc.